Zhou Chao, Zhao Jikai, Shao Jinchen, Li Wentao
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Oncotarget. 2017 Nov 18;8(64):107462-107468. doi: 10.18632/oncotarget.22489. eCollection 2017 Dec 8.
Tyroid transcription factor-1 (TTF-1) motivates the differentiation and development of bronchioloalveolar cells. The association of TTF-1 expression with prognosis in stage I adenocarcinoma is unclear. This study enrolled patients with resected stage I pulmonary adenocarcinoma who had TTF-1 immunostaining. All the corresponding clinicopathologic data including sex, age, smoking history, pathologic T stage, pathologic disease stage, surgical procedure, subtypes, follow-up records and adjuvant chemotherapy were investigated. Totally, 126 adenocarcinomas with TTF-1- and 2687 adenocarcinomas with TTF-1+ were subjected to the study. Among adenocarcinomas with TTF-1-, the major subtype was acinar-predominant adenocarcinomas, followed by invasive mucinous and papillary subtypes while acinar, papillary and minimally invasive adenocarcinoma were in the majority among adenocarcinomas with TTF-1+. The status of TTF-1 expression was not a significant factor for relapse-free survival (RFS) and overall survival (OS). Furthermore, there was no survival difference between the two groups (RFS: = 0.2474; OS: = 0.1480). When confined to stage IB adenocarcinomas with TTF-1-, whether received adjuvant chemotherapy made no difference to RFS and OS (RFS: = 0.2707; OS: = 1.000), as was the case in stage IB adenocarcinomas with TTF-1+ (RFS: = 0.9161; OS: = 0.1100). Within follow-up period, there was significant difference in post-recurrence survival (PRS) for TTF-1- patients compared with those TTF-1+ patients (Log-rank = 0.0113). However, regarding to the recurrence site, there was no difference between TTF-1- patients and TTF-1+ patients in patients with stage I adenocarcinoma ( = 0.771) In conclusion, there is no significant difference in RFS and OS between TTF-1- group and TTF-1+ group, but TTF-1 negative adenocarcinoma has significantly worse PFS in patients with stage I adenocarcinoma. Moreover, chemotherapeutic efficacy between TTF-1+ and TTF-1- stage IB adenocarcinomas did not differ.
甲状腺转录因子-1(TTF-1)促进细支气管肺泡细胞的分化和发育。TTF-1表达与Ⅰ期腺癌预后的关系尚不清楚。本研究纳入了接受TTF-1免疫染色的Ⅰ期肺腺癌切除患者。调查了所有相应的临床病理数据,包括性别、年龄、吸烟史、病理T分期、病理疾病分期、手术方式、亚型、随访记录和辅助化疗情况。总共126例TTF-1阴性腺癌和2687例TTF-1阳性腺癌纳入研究。在TTF-1阴性腺癌中,主要亚型是腺泡为主型腺癌,其次是浸润性黏液型和乳头型亚型;而在TTF-1阳性腺癌中,腺泡型、乳头型和微浸润腺癌占多数。TTF-1表达状态不是无复发生存期(RFS)和总生存期(OS)的显著影响因素。此外,两组之间无生存差异(RFS: = 0.2474;OS: = 0.1480)。当局限于TTF-1阴性的ⅠB期腺癌时,是否接受辅助化疗对RFS和OS无差异(RFS: = 0.2707;OS: = 1.000),TTF-1阳性的ⅠB期腺癌情况相同(RFS: = 0.9161;OS: = 0.1100)。在随访期内,TTF-1阴性患者与TTF-1阳性患者的复发后生存期(PRS)有显著差异(对数秩检验 = 0.0113)。然而,关于复发部位,Ⅰ期腺癌患者中TTF-1阴性患者与TTF-1阳性患者之间无差异( = 0.771)。总之,TTF-阴性组和TTF-1阳性组之间的RFS和OS无显著差异,但TTF-1阴性腺癌在Ⅰ期腺癌患者中的无进展生存期明显更差。此外,TTF-1阳性和TTF-1阴性的ⅠB期腺癌的化疗疗效无差异。
需注意,原文中部分“ = ”符号的含义不太明确,可能影响对整体内容的精准理解,以上翻译是基于现有文本尽量准确呈现。